跳转至内容
Merck
CN

V001881

黄嘌呤

p.a., 99%

别名:

2,6-二羟基嘌呤

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C5H4N4O2
化学文摘社编号:
分子量:
152.11
EC Number:
200-718-6
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
8733
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

grade

p.a.

assay

99%

SMILES string

O=C1NC(=O)c2nc[nH]c2N1

InChI

1S/C5H4N4O2/c10-4-2-3(7-1-6-2)8-5(11)9-4/h1H,(H3,6,7,8,9,10,11)

InChI key

LRFVTYWOQMYALW-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

存储类别

11 - Combustible Solids

wgk

WGK 3

法规信息

新产品

此项目有


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Gildas Bourdais et al.
PLoS genetics, 11(7), e1005373-e1005373 (2015-07-22)
Cysteine-rich receptor-like kinases (CRKs) are transmembrane proteins characterized by the presence of two domains of unknown function 26 (DUF26) in their ectodomain. The CRKs form one of the largest groups of receptor-like protein kinases in plants, but their biological functions
Avery G Frey et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(22), 8031-8036 (2014-05-21)
Although cells express hundreds of metalloenzymes, the mechanisms by which apoenzymes receive their metal cofactors are largely unknown. Poly(rC)-binding proteins PCBP1 and PCBP2 are multifunctional adaptor proteins that bind iron and deliver it to ferritin for storage or to prolyl
R Hille et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 9(11), 995-1003 (1995-08-01)
Xanthine oxidase and xanthine dehydrogenase are enzymes involved in the metabolism of purines and pyrimidines in various organisms. Their relationship to one another has been the subject of considerable debate, primarily because of their proposed roles in ischemia/reperfusion damage in
Carolyn F Deacon et al.
Expert opinion on investigational drugs, 19(1), 133-140 (2009-12-02)
Type 2 diabetes is a progressive disease for which current treatments are often unsatisfactory with respect to achieving therapeutic goals and unwanted side effects. Preclinical and clinical studies of linagliptin, a new oral antidiabetic agent, including data presented at Scientific
Ken Okamoto et al.
Current pharmaceutical design, 19(14), 2606-2614 (2012-11-03)
Xanthine oxidoreductase (XOR), a complex flavoprotein, catalyzes the metabolic reactions leading from hypoxanthine to xanthine and from xanthine to urate, and both reactions take place at the molybdenum cofactor. The enzyme is a target of drugs for therapy of gout

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持